You are here

FDA Approves Yutiq to Treat Chronic Noninfectious Uveitis

Only 18.7% of Patients Treated Had Uveitis Recurrence

The FDA approved Yutiq (Eyepoint Pharmaceuticals, Watertown, Massachusetts) for the treatment of chronic noninfectious uveitis, which affects the posterior part of the eye. The company plans to launch the drug in the first quarter of 2019.

In two randomized, sham injection-controlled, double-masked phase 3 clinical trials, YUTIQ (a non-bioerodible, intravitreal micro-insert containing 0.18 mg fluocinolone acetonide) significantly reduced recurrent uveitis flares compared to the sham. The most common adverse reactions were cataract development and an increase in intraocular pressure (IOP).

The first trial reached its principal efficacy endpoint at six months, with 18.4% of the patients treated with Yutiq having had a recurrence of uveitis compared with 78.6% of the control patients. The second trial showed that 21.8% of patients experienced uveitis recurrence at six months compared with 53.8% of the control patients. The efficacy in both studies was carried out to 12 months.

Follow-up data from 24 months and 36 months from the first trial are expected to be released by the end of 2018 and the first half of 2019, respectively.

Source:, October 15, 2018

More Headlines

iPSC Therapy Designed to Salvage Eye, Prevent Vision Loss
Health Outcomes Have No Improvement
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
Targeted Antibody for FGR3-Positive Mutation
Method Could Lead to Manufacturing Corneas for Transplants
Aggressive Disease Represents Around 6% of All New Cases of NHL
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Potential Life-Saving Device Can be Implanted in 2-LB Babies
New Therapy for Patients With HCC Who Previously Received Nexavar